Related Experiment Video
Updated: May 14, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Bupropion can close KATP channel and induce insulin secretion
Yifei Yang1, Kenju Shimomura, Kazuya Sakuma
1Department of Physiology, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|January 26, 2013
Summary
Bupropion, an antidepressant, may cause hyperinsulinism in newborns by affecting pancreatic beta-cells. This study reveals bupropion
Area of Science:
- Pharmacology
- Endocrinology
- Neonatal Medicine
Background:
- A recent case report linked maternal bupropion use during pregnancy to transient hyperinsulinism in a newborn.
- The underlying mechanism of bupropion-induced hyperinsulinism was previously unknown.
- No prior studies investigated the direct electrophysiological effects of bupropion on pancreatic beta-cells.
Purpose of the Study:
- To investigate the direct electrophysiological effects of bupropion on pancreatic beta-cells.
- To elucidate the pharmacological mechanism by which bupropion may induce hyperinsulinism.
- To assess the potential risks of maternal bupropion use during pregnancy.
Main Methods:
- Electrophysiological studies were conducted on pancreatic beta-cell membranes.
- The effect of bupropion on KATP channel activity was measured.
- Insulin secretion was assessed in response to bupropion exposure.
Main Results:
- Bupropion was found to inhibit KATP channel activity in pancreatic beta-cell membranes.
- Bupropion induced insulin secretion at relatively high concentrations.
- This study provides the first evidence of bupropion's direct electrophysiological action on pancreatic beta-cells.
Conclusions:
- Bupropion directly affects pancreatic beta-cells by inhibiting KATP channels and inducing insulin secretion.
- Maternal use of bupropion during pregnancy may pose a risk for developing hyperinsulinism in newborns.
- Further research is warranted to understand the clinical implications and management of bupropion-associated neonatal hyperinsulinism.
More Related Videos
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...